Fixing damaged nerves just got a lot less complicated thanks to an innovative device that doesn’t rely on stitches—and it’s officially been cleared by the FDA. The device, called Coaptium Connect, was developed by the French company Tissium and recently received de novo marketing authorization from the US Food and Drug Administration, making it the first fully atraumatic (meaning it doesn’t physically traumatize tissue) option to repair peripheral nerves.

Unlike traditional methods that use sutures, which can damage delicate nerves and require complex surgical skills, Coaptium Connect uses a smart combination of a 3D-printed bioresorbable chamber and a liquid polymer.

After the device is activated with light, the polymer bonds to the nerve ends inside the chamber. Over time, this chamber safely dissolves in the body, leaving no foreign material behind. In early clinical studies on patients with digital nerve injuries, the device achieved a 100% success rate, with all patients regaining full movement in their fingers and experiencing no pain a year later. This device is expected to shake up the $3.5 billion global nerve repair market by offering a simpler, safer alternative to sutures. Beyond nerve repair, Tissium hopes to adapt this technology for procedures like hernia repair and cardiovascular sealing.